Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.37 |
| ▸ | ADH1B | P00325 | 2/20 | 0.37 |
| ▸ | ADH1C | P00326 | 2/20 | 0.37 |
| ▸ | ADH1A | P07327 | 2/20 | 0.37 |
| ▸ | ADH7 | P40394 | 2/20 | 0.37 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25168564 | 0.84 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL11361562 | 0.74 | TSHR (0.30) | TSHR | |
| SCHEMBL28659093 | 0.72 | EPHX1 (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL28659266 | 0.72 | EPHX1 (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL28659270 | 0.72 | EPHX1 (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL28669049 | 0.72 | EPHX1 (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL28648780 | 0.72 | EPHX1 (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL28671496 | 0.72 | EPHX1 (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL28649716 | 0.72 | EPHX1 (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL27104136 | 0.72 | EPHX1 (0.48) | TSHRALDH1A1EPHX1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696568-B2 | PARKINSON'S DISEASE | FINETECH LTD. (IL) | 2004-02-24 | — | — | US | claimed |
| EP-1379526-A1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF CABERGOLINE AND RELATED COMPOUNDS | Finetech Laboratories Ltd. (IL) | 2004-01-14 | — | — | EP | claimed |
| US-20020177709-A1 | Novel process and intermediates for production of cabergoline and related compounds | FINETECH PHARMACEUTICAL LTD. (IL) | 2002-11-28 | — | — | US | claimed |
| WO-2002085902-A1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF CABERGOLINE AND RELATED COMPOUNDS | FINETECH LABORATORIES LTD. (IL) | 2002-10-31 | — | — | WO | claimed |
| EP-1379526-A1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF CABERGOLINE AND RELATED COMPOUNDS | Finetech Laboratories Ltd. (IL) | 2004-01-14 | — | — | EP | disclosed |
| US-20020177709-A1 | Novel process and intermediates for production of cabergoline and related compounds | FINETECH PHARMACEUTICAL LTD. (IL) | 2002-11-28 | — | — | US | disclosed |
| WO-2002085902-A1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF CABERGOLINE AND RELATED COMPOUNDS | FINETECH LABORATORIES LTD. (IL) | 2002-10-31 | — | — | WO | disclosed |
| EP-0729488-A1 | POLYKETONE POLYMER COMPOSITION | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1996-09-04 | — | — | EP | disclosed |
| US-5486581-A | IODIDE SALTS | SHELL OIL COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995014056-A1 | POLYKETONE POLYMER COMPOSITION | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1995-05-26 | — | — | WO | disclosed |
| US-4658062-A | Amine terminated polybutadiene compositions and preparation thereof | ATLANTIC RICHFIELD COMPANY (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0206714-A1 | Process for the preparation of an amine terminated polybutadiene | ELF ATOCHEM S.A. (FR) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177709-A1 | Novel process and intermediates for production of cabergoline and related compounds | NR5A1, ADCY5, GNRHR | TSHR 426/4885ALDH1A1 2658/4885ZDHHC20 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.